Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
93 hedge funds and large institutions have $222M invested in Concert Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 42 reducing their positions, and 27 closing their positions.
13% less capital invested
Capital invested by funds: $255M → $222M (-$32.6M)
16% less funds holding
Funds holding: 111 → 93 (-18)
36% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 42
59% less call options, than puts
Call options by funds: $176K | Put options by funds: $432K
67% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$25.9M |
| 2 |
RI
RTW Investments
New York
|
+$10.9M |
| 3 |
First Manhattan
New York
|
+$6.69M |
| 4 |
Millennium Management
New York
|
+$6.51M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$6.1M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$4.42M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.77M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.34M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$2.62M |
CNCE Hedge Fund Activity: Q4 2018 in Review
93 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q4 2018, worth a combined $222M — down 13% from $255M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of CNCE and 9 opened new positions — a net loss of 18 holders — while 42 trimmed existing stakes and 27 added.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $25.9M. The largest seller was BVF Inc, cutting an estimated $6.1M.
- 93 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q4 2018, down from 111 in Q3 2018.
- Funds reported $222M of Concert Pharmaceuticals, Inc. stock for Q4 2018, down 13% quarter-over-quarter.
- 9 funds opened new Concert Pharmaceuticals, Inc. positions in Q4 2018 and 27 closed out, a net change of -18 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q4 2018 was Perceptive Advisors, an estimated $25.9M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q4 2018 was BVF Inc, an estimated $6.1M sold.
Based on aggregated 13F filings for Q4 2018.